Bausch Health Companies Inc. filings document regulatory disclosures for a global diversified pharmaceutical company incorporated in British Columbia. The record includes Form 8-K reports for quarterly and annual operating results, Regulation FD updates, clinical-program disclosures, material agreements, debt exchanges and credit-agreement refinancing involving Bausch Health and its subsidiaries, including Bausch + Lomb.
Proxy materials describe annual meeting matters, director elections, auditor approval, executive compensation votes and governance procedures. Other current reports address compensatory arrangements, including performance share unit settlement terms, and capital-structure disclosures tied to senior secured notes, guarantees, collateral arrangements and refinancing transactions.
Bausch Health Companies Inc. insider filing reports a large share purchase by a major shareholder’s managed funds. On 11/25/2025, investment funds managed by Paulson & Co. acquired 2,500,000 shares of Bausch Health common stock at $6.25 per share. After this transaction, the funds collectively held 73,255,869 shares, reported as indirectly owned "By Managed Funds." The reporting person is identified as a director and 10% owner, and the filing notes that Paulson & Co. and John Paulson may be deemed indirect beneficial owners through their roles with the funds, while formally disclaiming beneficial ownership beyond any pecuniary interest.
Bausch Health Companies Inc. (BHC) has launched exchange offers to swap its outstanding 4.875% and 11.00% Senior Secured Notes due 2028 for up to $1.6 billion aggregate principal amount of new 10.00% Senior Secured Notes due 2032 issued by an indirect subsidiary. The new notes will form a single series with an existing $4.4 billion tranche of 10.00% Senior Secured Notes due 2032 issued earlier in 2025.
Participation is limited to eligible institutional and non‑U.S. holders under U.S. and international securities laws, and acceptances will target a mix of approximately 52.6% 11.00% notes and 47.4% 4.875% notes, subject to a maximum of $1.6 billion. Holders representing about $1,545 million of existing notes, or roughly 46% of the total outstanding, have signed a transaction support agreement committing to tender their notes and to take commercially reasonable actions to facilitate completion of the offers.
Nomura Holdings filed an amended Schedule 13G reporting beneficial ownership of Bausch Health Companies Inc. common shares. Through wholly owned subsidiary Nomura Global Financial Products, Inc., the group reports beneficial ownership of 15,708,085 shares, representing 4.2% of the class.
The filing lists shared voting and dispositive power over 15,708,085 shares and no sole voting or dispositive power. The percentage is based on 370,473,221 shares outstanding as of September 30, 2025, as disclosed by the issuer. The certification states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control.
Bausch Health Companies Inc. reported stronger Q3 2025 results. Revenue reached $2.681 billion versus $2.510 billion a year ago, and operating income rose to $619 million from $318 million. Net income attributable to Bausch Health was $179 million, compared with a loss of $85 million, translating to diluted EPS of $0.48.
For the first nine months, revenue was $7.470 billion and net income attributable to Bausch Health was $269 million with diluted EPS of $0.72. Operating cash flow was $905 million. Cash and cash equivalents were $1.308 billion, and total assets were $26.824 billion.
Debt and equity shifted due to refinancing: current portion of long-term debt decreased to $579 million from $2.674 billion, while non‑current long-term debt increased to $20.463 billion. Total equity improved to $356 million from a deficit of $(322) million at year‑end. The company acquired DURECT for $84 million, expensing $81 million as acquired IPR&D tied to Larsucosterol. Bausch + Lomb remained approximately 88% owned, and the company continues to evaluate completing the B+L separation.
Common shares outstanding were 370,516,926 as of October 24, 2025.
Bausch Health Companies Inc. filed a current report to let investors know it has released its financial results for the quarter ended September 30, 2025. On October 29, 2025, the company issued a press release covering its results of operations and other financial information for that quarter, which is included as Exhibit 99.1.
The company states that this information is being furnished, not filed, so it is not subject to certain liability provisions of the Exchange Act and will not be incorporated by reference into securities offering documents. The filing is mainly a formal notice pointing readers to the detailed third-quarter 2025 results contained in the attached press release.
Bausch Health Companies Inc. reported the results of a Special Meeting of Shareholders held on October 7, 2025. Shareholders voted on an ordinary resolution to ratify, confirm and approve the adoption of the company’s Amended and Restated Shareholder Rights Plan Agreement dated April 14, 2025 and amended and restated on August 25, 2025. The resolution was approved, with 178,244,775 votes cast for and 40,130,633 votes cast against. The Rights Plan Agreement is described in detail in the company’s Management Proxy Circular and Proxy Statement dated August 27, 2025.
Amendment corrects previously reported insider holdings. This Form 4/A updates an earlier filing to state that John Paulson indirectly beneficially owned 70,755,869 common shares of Bausch Health Companies Inc. as of the 09/30/2025 transaction date. The amendment says the corrected amount matches what was reported on a prior Form 4 filed 08/14/2025 and attributes the holdings to funds managed by Paulson Capital Inc., while the reporting person disclaims direct beneficial ownership except for any pecuniary interest. The filing was signed by an attorney-in-fact on 10/06/2025.
John Paulson, a director of Bausch Health Companies Inc. (BHC), received 9,689 restricted share units on 09/30/2025 as compensation for board service for the quarter ended that date; each unit vests into one common share. After the grant, Mr. Paulson directly beneficially owns 351,128 common shares. In addition, he may be deemed an indirect beneficial owner of 32,791,702 common shares held by investment funds managed by Paulson Capital Inc., although the filing disclaims beneficial ownership except to the extent of any pecuniary interest. The transaction was reported on Form 4 and signed by an attorney-in-fact on 10/02/2025.
Bausch Health Companies director Sandra Leung was granted 3,673 restricted share units (RSUs) issued in lieu of cash compensation for her service on the board for the quarter ending September 30, 2025. Each RSU represents a contingent right to receive one common share. After the award, the reporting person beneficially owned 33,822 common shares. The transaction was reported on a Form 4 and executed under transaction code V, with the RSUs recorded at $0 price as issued units rather than an open-market purchase.
Bausch Health Companies Inc. director Amy B. Wechsler received 1,065 restricted share units on 09/30/2025 issued in lieu of cash compensation for board service. Each restricted share unit represents a contingent right to one common share and was reported as having a $0 cash price. After the grant, the reporting person beneficially owned 265,452 common shares. The Form 4 was signed by an attorney-in-fact on 10/02/2025.